000276211 001__ 276211
000276211 005__ 20240229154958.0
000276211 0247_ $$2doi$$a10.1182/blood.2022018669
000276211 0247_ $$2pmid$$apmid:37217183
000276211 0247_ $$2ISSN$$a0006-4971
000276211 0247_ $$2ISSN$$a1528-0020
000276211 0247_ $$2altmetric$$aaltmetric:148942223
000276211 037__ $$aDKFZ-2023-01023
000276211 041__ $$aEnglish
000276211 082__ $$a610
000276211 1001_ $$0P:(DE-He78)7b847bc226706f4fc5a573f1483c49d9$$aNicolay, Jan$$b0$$eFirst author$$udkfz
000276211 245__ $$aDimethyl fumarate treatment in relapsed and refractory cutaneous T cell lymphoma - a multicenter phase II study.
000276211 260__ $$aWashington, DC$$bAmerican Society of Hematology$$c2023
000276211 3367_ $$2DRIVER$$aarticle
000276211 3367_ $$2DataCite$$aOutput Types/Journal article
000276211 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1693574401_4718
000276211 3367_ $$2BibTeX$$aARTICLE
000276211 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000276211 3367_ $$00$$2EndNote$$aJournal Article
000276211 500__ $$a#EA:A370#LA:D030# / 2023 Aug 31;142(9):794-805
000276211 520__ $$aTargeted therapies for cutaneous T-cell lymphoma (CTCL) are limited and curative approaches are lacking. Furthermore, relapses and drug induced side effects are major challenges in the therapeutic management of CTCL patients creating an urgent need for new, effective therapies. Pathologic constitutive NF-κB activity leads to apoptosis resistance in CTCL cells and thus represents a promising therapeutic target in CTCL. In a preclinical study we showed the potential of dimethyl fumarate (DMF) to block NF-κB and specifically kill CTCL cells (Nicolay et al.: Blood 2016). To translate these findings into a clinical setting, we performed a multicentric phase II study evaluating oral DMF therapy in 25 patients with CTCL stage Ib-IV over 24 weeks (EudraCT number 2014-000924-11/NCT number NCT02546440). Endpoints were safety and efficacy. We evaluated skin involvement (mSWAT), pruritus, quality of life and blood involvement if applicable as well as translational data. In the skin, 7/23 patients (30.4%) showed a response with >50% reduction in mSWAT. Patients with high tumor burden in skin and blood responded best to DMF therapy. Although not generally significant, DMF also improved pruritus in several patients. Response in the blood was mixed, but we confirmed the NF-κB inhibiting mechanism of DMF in the blood. The overall tolerability of the DMF therapy was very favorable with mostly mild side effects. In conclusion, our study presents DMF as an effective and excellently tolerable therapeutic option in CTCL to be further evaluated in a phase III study or real-life patient care as well as in combination therapies.
000276211 536__ $$0G:(DE-HGF)POF4-314$$a314 - Immunologie und Krebs (POF4-314)$$cPOF4-314$$fPOF IV$$x0
000276211 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000276211 7001_ $$0P:(DE-He78)4996ebdbd03226d4bfae41c0f9066a4b$$aMelchers, Susanne$$b1$$udkfz
000276211 7001_ $$00000-0003-4994-8719$$aAlbrecht, Jana D$$b2
000276211 7001_ $$aAssaf, Chalid$$b3
000276211 7001_ $$00000-0002-4433-2387$$aDippel, Edgar$$b4
000276211 7001_ $$00000-0003-2683-6028$$aStadler, Rudolf$$b5
000276211 7001_ $$00000-0002-7398-4261$$aWehkamp, Ulrike$$b6
000276211 7001_ $$00000-0002-6293-2554$$aWobser, Marion$$b7
000276211 7001_ $$00000-0002-7530-6560$$aZhao, Jing$$b8
000276211 7001_ $$aBurghaus, Ina$$b9
000276211 7001_ $$aSchneider, Sven$$b10
000276211 7001_ $$aGülow, Karsten$$b11
000276211 7001_ $$aGoerdt, Sergij$$b12
000276211 7001_ $$00000-0002-1792-1768$$aSchürch, Christian M$$b13
000276211 7001_ $$aUtikal, Jochen$$b14
000276211 7001_ $$0P:(DE-He78)92492c6eae05ee58973fc142c9201e3d$$aKrammer, Peter$$b15$$eLast author
000276211 773__ $$0PERI:(DE-600)1468538-3$$a10.1182/blood.2022018669$$gp. blood.2022018669$$n9$$p794-805$$tBlood$$v142$$x0006-4971$$y2023
000276211 909CO $$ooai:inrepo02.dkfz.de:276211$$pVDB
000276211 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)7b847bc226706f4fc5a573f1483c49d9$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000276211 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4996ebdbd03226d4bfae41c0f9066a4b$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000276211 9101_ $$0I:(DE-588b)2036810-0$$60000-0003-4994-8719$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000276211 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)92492c6eae05ee58973fc142c9201e3d$$aDeutsches Krebsforschungszentrum$$b15$$kDKFZ
000276211 9131_ $$0G:(DE-HGF)POF4-314$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImmunologie und Krebs$$x0
000276211 9141_ $$y2023
000276211 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2022-11-25
000276211 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-25
000276211 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-25
000276211 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-21
000276211 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-21
000276211 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-10-21
000276211 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-21
000276211 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-21
000276211 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-21
000276211 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-10-21
000276211 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-10-21
000276211 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBLOOD : 2022$$d2023-10-21
000276211 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-21
000276211 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-21
000276211 915__ $$0StatID:(DE-HGF)9920$$2StatID$$aIF >= 20$$bBLOOD : 2022$$d2023-10-21
000276211 9202_ $$0I:(DE-He78)D030-20160331$$kD030$$lImmungenetik$$x0
000276211 9201_ $$0I:(DE-He78)A370-20160331$$kA370$$lKKE Dermatoonkologie$$x0
000276211 9201_ $$0I:(DE-He78)D030-20160331$$kD030$$lImmungenetik$$x1
000276211 9200_ $$0I:(DE-He78)A370-20160331$$kA370$$lKKE Dermatoonkologie$$x0
000276211 980__ $$ajournal
000276211 980__ $$aVDB
000276211 980__ $$aI:(DE-He78)A370-20160331
000276211 980__ $$aI:(DE-He78)D030-20160331
000276211 980__ $$aUNRESTRICTED